



SUVN-911

Selective $\alpha 4\beta 2$ nAChR Antagonist

**Addressing the Limitations of Current SOC for
Major Depressive Disorders**

Phase 1 in progress (USA)



SUVN-911: Key Features





- Novel, potent and selective $\alpha 4\beta 2$ nAChR antagonist
- Excellent ADME properties with no drug-drug interaction liability
- Robust efficacy in animal models of depression
- Rapid onset of action, no sexual dysfunction and procognitive effects
- Increase in cortical serotonin levels which may partly explain the antidepressant property
- Translatable biomarker available for POC study
- Demonstrated good safety margin in preclinical species
- Well protected intellectual property in all major countries
- Safe and well tolerated in healthy subjects in Phase 1 study
- Excellent human pharmacokinetics
- Projected human efficacy concentrations achieved in Phase 1 study


SUVN-911: Key Biology Results



Dominant Submissive Assay



Target Engagement



Addresses major limitations of current MDD therapeutics by offering

Rapid onset of action, No sexual dysfunction and Procognitive effects

SUVN-911: Clinical studies summary and current status



- Well tolerated in healthy human subjects
- No serious adverse events
- Projected efficacious concentrations were achieved in single and multiple dose studies
- No clinically significant findings in vital signs, clinical laboratory parameters and ECG parameters

Current status: Phase 1 in progress



Contacts:

Venkat Jasti

Chairman & CEO

E-mail: info@suven.com

Ramakrishna Nirogi

Vice President, Discovery Research

E-mail: nvsrk@suven.com